Concr is a mission-driven techbio company that uses established methods from astrophysics to accurately predict patient outcomes and treatment response to novel and existing cancer therapies. Their unique approach allows iterative learning between disparate and fragmented data across all stages of a drug’s journey into the clinic, removing the need for ‘big data’ and yielding the most accurate multi-modal tumor models.

Concr Pty Ltd

Concr is a mission-driven techbio company that uses established methods from astrophysics to accurately predict patient outcomes and treatment response to novel and existing cancer therapies.  

Our unique approach allows iterative learning between disparate and fragmented data across all stages of a drug’s journey into the clinic, removing the need for ‘big data’ and yielding most accurate multi-modal tumour models. 

Using Concr’s cloud native platform – FarrSight® – researchers can computationally simulate clinical trials, make advanced predictions about biomarkers, and perform standard bioinformatics analyses directly. 

Concr is headquartered in London, with a wholly-owned subsidiary in Brisbane, Australia. The company is a venture capital-backed enterprise, with investors including the University of Cambridge Enterprise, R42 Group, Oncology Ventures, Debiopharm, Cambridge Angels, Deep Science Ventures and SyndicateRoom.

Illumina

Accelerate@Babraham

Avonmore Developments

KQ Labs

R42 Group

University of Cambridge Enterprise

Deep Science Ventures

Cambridge Angels group

Concr

📣 Exciting news! We’ve been named one of Hello Tomorrow's Deep Tech Pioneers! 

Come and meet us at the Hello Tomorrow Global Summit next spring in Paris, alongside industry leaders, investors, researchers and experts in the deep tech ecosystem from all over the world.

More info here 👉  https://bit.ly/ht-24

A special thanks to Loukik Arora, Ph.D. for the encouragement to apply 🙏 

 #DeepTechPioneer #HelloTomorrow #innovation #FromCosmologytoOncology

Looking forward to connect with old and new colleagues tomorrow at this exciting annual event, brought together by Cancer Research Horizons.

Get in touch with our CBO Irina Babina if you're attending and would like to learn more about how we predict patient response and outcomes to increase drug success.

https://lnkd.in/ewggAfzk

📍 Royal Society of Medicine, London
🕘 09:00 - 17:00

#techbio #innovation #precisiononcology #biomarkers #ai #machinelearning #data 

It’s just around the corner!

Concr is presenting at #BIOEurope next week, and attendees can now watch our presentation on demand, and throughout the conference.

Whether you’re a drug developer looking to de-risk development and increase value of your asset; or a Series A investor looking for a techbio opportunity, get in touch with our CBO Irina Babina for a 1:1 meeting now. 

Register to watch our presentation: https://bit.ly/49gqwNn

#biomarkers #precisionmedicine #techbio #drugdevelopment #investment #seriesA #lifesciences #FromCosmologytoOncology

CO:CONCR

Concr Pty Ltd

Financials Not Available